WO2011066441A1 - Dispositifs médicaux implantables comportant des couches de surface microporeuses et procédé pour réduire la réponse des corps étrangers à ceux-ci - Google Patents

Dispositifs médicaux implantables comportant des couches de surface microporeuses et procédé pour réduire la réponse des corps étrangers à ceux-ci Download PDF

Info

Publication number
WO2011066441A1
WO2011066441A1 PCT/US2010/058078 US2010058078W WO2011066441A1 WO 2011066441 A1 WO2011066441 A1 WO 2011066441A1 US 2010058078 W US2010058078 W US 2010058078W WO 2011066441 A1 WO2011066441 A1 WO 2011066441A1
Authority
WO
WIPO (PCT)
Prior art keywords
micrometers
pores
microporous
biomaterial
porogens
Prior art date
Application number
PCT/US2010/058078
Other languages
English (en)
Inventor
Andrew J. Marshall
Michel Alvarez
Max G. Maginness
Original Assignee
Healionics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/026107 external-priority patent/WO2011065987A1/fr
Application filed by Healionics Corporation filed Critical Healionics Corporation
Priority to US13/082,760 priority Critical patent/US8372423B2/en
Priority to EP11724832.8A priority patent/EP2555810B1/fr
Priority to CN201180027977.7A priority patent/CN103037911B/zh
Priority to PCT/US2011/031764 priority patent/WO2011127395A1/fr
Priority to KR1020127029276A priority patent/KR101813300B1/ko
Publication of WO2011066441A1 publication Critical patent/WO2011066441A1/fr
Priority to US13/718,847 priority patent/US8647393B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/146—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/146—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/02—Methods for coating medical devices

Definitions

  • This disclosure relates to surface-coated implantable medical devices.
  • Implantable medical devices such as implantable biosensors, breast implants, prostheses, surgical mesh implants and neuromodulation leads, once implanted into a body, frequently induce an inflammatory reaction of the body.
  • This common problem is called the foreign body response (FBR).
  • FBR foreign body response
  • host macrophages are attracted to the surface of the implant.
  • the macrophages arrive in sufficient numbers to spread over all surfaces of the implant that interface with the host tissue.
  • these macrophages trigger a cascade of cytokines and chemokines that recruit fibroblasts and other extracellular matrix-building cells to the tissue adjacent to the implant.
  • the end result of the FBR is the formation of a dense, fibrous, largely avascular capsule that partially or completely surrounds the device. This foreign body encapsulation can effectively isolate the implantable device from the surrounding tissue, physically, chemically and electrically.
  • FBR limits the performance and operating lives of most implantable devices, which limitation is particularly debilitating in devices that are designed to continuously monitor or report data of measurements to an external data processing unit. For example, there have been many attempts to develop implantable devices that can continuously record blood glucose monitoring data; however, the FBR effects have frustrated these efforts. Similarly, proper functioning of neuromodulation electrodes and other electrostimulation devices is adversely affected by the FBR. Buildup of dense fibrous capsule tissue increases the electrical impedance from the electrodes to
  • Tissue implants used in cosmetic and reconstructive surgeries are another type of implantable devices, the functions of which can be adversely affected by the FBR.
  • fibrous capsule can form and contract around the implant (e.g., breast implant), causing it to harden. The condition often requires the implant to be surgically removed.
  • FBR biological response
  • porous biomaterials with pore sizes on the order of cellular dimensions have been shown to alter the FBR.
  • porous biomaterials with a pore size that is large enough to allow macrophage penetration was shown to increase vascularity in the capsule tissue.
  • Increased vascularity was shown to correlate with improved diffusion and plasma- exchange properties.
  • Implantable devices coated with microporous surface layers with macrotopographic features that improve bio-integration at the interface of the implantable devices and the surrounding tissue.
  • One embodiment provides a microporous biomaterial with macrotopographic surface features, wherein the microporous biomaterial has a continuous contour and continuously interconnecting pores, wherein substantially all the pores are each interconnected to at least 2 other pores, a mean diameter of the pores is between about 5 and about 100 micrometers, and any two adjacent pores are connected by a throat, a mean throat diameter of the throats being between about 5 micrometers and about 50 micrometers, and wherein the macrotopography is defined by a plurality of peaks and valleys, wherein each peak comprises a plurality of pores and has a height of between about 100 micrometers and about 2000 micrometers.
  • the mean pore diameter is between about 20 and about 40 micrometers
  • the height of each peak is between about 100 micrometers and about 500 micrometers, or between about 200 micrometers and about 1000 micrometers, or between about 500 micrometers and about 2000 micrometers, or between about 500 micrometers and about 1000 micrometers.
  • the microporous biomaterial comprises an open-cell structure throughout the entire microporous biomaterial.
  • the biomaterial is biodegradable.
  • the biomaterial is a hydrogel, silicone rubber, expanded
  • the microporous biomaterial comprises a conductive polymer or metalized polymer, or the biomaterial has a thickness of at least 40 micrometers excluding the height of the peaks.
  • a further embodiment provides an implantable device comprising: a device body; and a microporous surface layer with macrotopographic features, wherein the microporous surface layer has a continuous contour and continuously interconnecting pores, wherein substantially all the pores are each interconnected to at least 2 other pores, a mean diameter of the pores is between about 5 and about 100 micrometers, and any two adjacent pores are connected by a throat, a mean throat diameter of the throats being between about 5 micrometers and about 50 micrometers, and wherein the
  • macrotopography is defined by a plurality of peaks and valleys, wherein each peak comprises a plurality of pores and has a height of between about 100 micrometers and about 2000 micrometers.
  • the microporous surface layer of the implantable device has a thickness of at least 40 micrometers excluding the height of the peaks. In other embodiments, the mean pore diameter is between about 20 and about 40
  • the implantable device further comprises an intermediate layer interposed between the device body and the microporous surface layer such as an adhesive layer or a conformal sheath that covers a part of or an entire native surface of the device body.
  • a further embodiment provides an implantable device comprising a device body; and a textured surface layer overlying the device body, wherein the textured surface layer comprises one or more granules of a microporous biomaterial, the granules forming a surface macrotopography that includes a plurality of peaks and valleys, each peak having a height of between about 100 micrometers and about 2000 micrometers, and wherein each granule comprises a plurality of interconnecting pores having a mean pore diameter of between about 5 and 100 micrometers, and any two adjacent pores are connected by a throat, a mean throat diameter of the throats being between 5 and 50 micrometers.
  • the mean pore diameter is between about 20 and about 40 micrometers.
  • the height of each peak of the microporous surface is between about 100 micrometers and about 500 micrometers, between about 200 micrometers and about 1000 micrometers, between about 500 micrometers and about 2000 micrometers, or between about 500 micrometers and about 1000 micrometers.
  • the implantable device further comprises an intermediate layer interposed between the device body and the microporous surface layer such as an adhesive layer or a conformal sheath that covers a part of or an entire native surface of the device body.
  • the granules cover the implantable device more than 80%, or more than 90% of a total area of a native surface of the device body.
  • micro-porogens such that points of contact and interstitial spaces between adjacent micro-porogens are formed, wherein the micro-porogens have a mean micro-porogen diameter that is between about 5 micrometers and about 100 micrometers;
  • the macro-porogens comprise salt crystals, thermoplastic beads, poly(methyl methacrylate) or polystyrene beads.
  • the micro-porogens comprise salt crystals, thermoplastic beads, poly(methyl methacrylate) or polystyrene beads.
  • the biomaterial is silicone rubber or hydrogel.
  • the dissolvable mold surface is poly(methyl methacrylate) or polystyrene.
  • a further embodiment provides A method comprising: implanting a microporous biomaterial with macrotopographic surface features, wherein the
  • microporous biomaterial has a continuous contour and continuously interconnecting pores, wherein substantially all the pores are each interconnected to at least 2 other pores, a mean diameter of the pores is between about 5 and about 100 micrometers, and any two adjacent pores are connected by a throat, a mean throat diameter of the throats being between about 5 micrometers and about 50 micrometers, and wherein the macrotopography is defined by a plurality of peaks and valleys, wherein each peak comprises a plurality of pores and has a height of between about 100 micrometers and about 2000 micrometers.
  • the microporous biomaterial is a surface layer overlying an implantable device.
  • a further embodiment provides a method comprising: implanting an implantable device comprising: a device body; and a microporous surface layer with macrotopographic features, wherein the microporous surface layer has a continuous contour and continuously interconnecting pores, wherein substantially all the pores are each interconnected to at least 2 other pores, a mean diameter of the pores is between about 5 and about 100 micrometers, and any two adjacent pores are connected by a throat, a mean throat diameter of the throats being between about 5 micrometers and about 50 micrometers, and wherein the macrotopography is defined by a plurality of peaks and valleys, wherein each peak comprises a plurality of pores and has a height of between about 100 micrometers and about 2000 micrometers.
  • a further embodiment provides a method comprising: implanting an implantable device a device body; and a textured surface layer overlying the device body, wherein the textured surface layer comprises one or more granules of a microporous biomaterial, the granules forming a surface macrotopography that includes a plurality of peaks and valleys, each peak having a height of between about 100 micrometers and about 2000 micrometers, and wherein each granule comprises a plurality of interconnecting pores having a mean pore diameter of between about 5 and 100 micrometers, and any two adjacent pores are connected by a throat, a mean throat diameter of the throats being between 5 and 50 micrometers.
  • Figure 1 is a Scanning Electron Micrograph (SEM) of microporous silicone scaffold with spherical pore diameter of about 30-35 micrometers and pore connections (throat) of about 12-14 micrometers in diameter.
  • Figure 2 shows tissue sections of sphere-templated microporous scaffolds of various pore diameters implanted subcutaneously in mice for 28 days; sections have been stained with BM8 macrophage marker. Pore sizes: (A) 20 micrometers; (B) 35 micrometers; (C) 50 micrometers; (D) 70 micrometers (E) 90 micrometers.
  • the scaffold with 35 -micrometer pores contains the highest concentration of macrophages.
  • Figure 3 shows tissue section of a microporous scaffold implanted subcutaneously into a pig for 28 days and stained with Hemotoxylin and Eosin.
  • A Scaffold with stained cellular ingrowth into pores;
  • B Surrounding tissue.
  • Figure 4 schematically shows a cross-sectional view of an embodiment of the present disclosure, in which a device is covered with a microporous surface layer having macrotopographic features formed by granules of a microporous biomaterial.
  • Figure 5 shows an SEM of a monolayer of 300-500 micrometer granules of microporous silicone adhered to solid silicone.
  • Figure 6 schematically illustrates the effect of the granule size on the concentration of surface pores that are directly exposed to adjacent tissue.
  • Figure 7 schematically illustrates a device with granules of different sizes attached to its surface.
  • Panel A Uniform size granules
  • Panel B Mixture of granules having different sizes
  • Panel C Mixture of two sizes of granules
  • Panel D Granules of different sizes successively applied to the device.
  • Figure 8 shows a hernia repair mesh (polypropylene) with mesh fibers coated with adherent monolayer of 300-500-micrometer granules of microporous silicone.
  • Figure 9 is an SEM of a continuously microporous silicone scaffold with macrotopographic features.
  • Figure 10 is an SEM of a single peak of a continuously microporous silicone scaffold with macrotopographic features.
  • the present disclosure is directed to implantable devices having
  • microporous, textured surface layers which serve to improve bio-integration at the interface between the implanted devices and the surrounding tissue.
  • microporous surface layers that have textured or macrotopographic features are capable of minimizing or eliminating the FBR to the implanted device.
  • implantable devices or “implanted device” refers to any type of medical device that is totally or partly introduced, surgically or medically, into the body of a subject (a human or an animal) or by medical intervention into a natural orifice, and which is intended to remain there after the procedure.
  • An implantable device typically includes a device body and a surface layer. The device body carries out a particular function once implanted into the subject.
  • Exemplary device bodies include, without limitation, soft tissue implants (e.g., breast implants, muscle prosthesis), implantable biosensors (e.g., glucose monitors), mass transfer devices (e.g., a drug infusing device), immunoisolation devices, electrostimulation devices, tissue expanders, tissue scaffolds (for supporting tissue growth), gastrointestinal liners, surgical mesh implants, and percutaneous devices (e.g., catheters, feeding tubes, and dialysis ports).
  • soft tissue implants e.g., breast implants, muscle prosthesis
  • implantable biosensors e.g., glucose monitors
  • mass transfer devices e.g., a drug infusing device
  • immunoisolation devices e.g., electrostimulation devices
  • tissue expanders e.g., tissue scaffolds (for supporting tissue growth)
  • gastrointestinal liners e.g., surgical mesh implants
  • percutaneous devices e.g., catheters, feeding tubes, and dialysis ports.
  • surface layer refers to a layer of microporous biomaterial overlying a native surface of the device body, the native surface being any part or all of the surface of the device body that, once implanted would be in direct contact with tissue but for the surface layer.
  • the surface layer may be essentially a microporous tissue scaffold that facilitates the integration of the implanted device and its surrounding tissue, i.e., the tissue that is adjacent to the implanted device but outside of the micropores.
  • “Microporous biomaterial” or “microporous scaffold” refers to a biocompatible material comprising an array of spherical or substantially spherical pores that are substantially connected. As used herein, “substantially connected” means that essentially every pore is connected to at least two, and preferably at least four other pores. Microporous scaffolds have been shown to allow tissue ingrowth and promote
  • angiogenesis e.g., formation of blood vessels.
  • FIG 1 shows a Scanning Electron Micrograph (SEM) of a porous silicon scaffold.
  • Each pore 10 has a diameter "D.”
  • An opening caused by two pores partially fused into each other is called a throat (visualized as the dark “holes” 12 in Figure 1).
  • the throat also has a diameter "d.”
  • the diameter of a throat might range from infinitesimally small, when two pores are barely fused, to nearly the diameter of a pore, when two pores are almost completely fused.
  • the microporous material may have a pre-determined pore diameter and throat diameter.
  • the throat diameters (d) are approximately 15% to approximately 40% of the pore diameters (D) in order, according to non-limiting theory, to optimize the pro-angiogenic and anti-fibrotic properties of the microporous materials.
  • the mean pore diameter can be between 10 and 100 micrometers.
  • the preferred pore diameter is between 20 and 40 micrometers, between 30 and 40 micrometers, between 25 and 35 micrometers, between 20 and 30 micrometers, or between 25 and 30 micrometers.
  • the majority of the pores in the scaffold will be of such a preferred pore size.
  • the geometries of the pores may, according to non-limiting theory, constrain the invading macrophage cells and prevent them from spreading or aggregating into giant cells.
  • the pore geometry thus may provide spatial cues that trigger the macrophages to secrete anti-fibrotic and pro-angiogenic factors.
  • Figure 2 shows scaffolds with substantially spherical pores in sizes of 20, 35, 50, 70, and 90 micrometers and with 10-micrometer throats. As shown, the scaffold with 35 micrometer pore size is colonized with a higher concentration of macrophages than are the other porous scaffolds.
  • Figure 3 further shows a histological cross-section of a prior art microporous biomaterial displaying the interface with the surrounding tissue and the cellular ingrowth into the pores. As shown, the tissue at the material interface (e.g., leftmost area of panel B) is not fibrotic, but loose and vascular.
  • the mean diameter of the connection between the pores may in certain preferred embodiments be between 5 and 50 micrometers.
  • the preferred diameter of the pore connections is between 8 and 25 micrometers, more preferably between 10 and 20 micrometers.
  • the majority of the pore connections will be of the preferred size.
  • a macrophage cell diameter is typically about 10 to 15 micrometers in size, so the pore connections should be large enough to accommodate facile cell migration though the scaffold.
  • vascular endothelial capillaries are typically about 10 micrometers in diameter, so the scaffold should have pore connections large enough to permit ingrowth of a capillary network to support and nourish cells inside the scaffold.
  • the anti-fibrotic and pro-angiogenic factors can be further concentrated, which leads to an improved bio-integration between the implanted device and the surrounding tissue.
  • a monolayer of the microporous biomaterial in granular form provides textured surface features.
  • Figure 4 shows schematically one configuration of an implantable device 30 that comprises a device body 40, and a layer 44 of granules 50 of a microporous biomaterial positioned thereupon. Also shown in Figure 4 is an optional intermediate layer 44 (e.g., a silicone adhesive layer) interposed between the device body 40 and the monolayer 44.
  • an optional intermediate layer 44 e.g., a silicone adhesive layer
  • the granules define a surface macrotopography that include peaks 60 and valleys 70.
  • the peaks and valleys correlate to the sizes of the granules and the space therebetween, respectively. More specially, a peak represents a projection or protrusion in the surface macrotopography, whereas a valley represents a depression in the surface macrotopography and is a space defined by two or more adjacent peaks.
  • the floor of the valley may be an exposed part of the surface of the underlying device body or porous granules.
  • the height (“H") of the peak is typically measured relative to the floor of the adjacent valley (e.g., the surface uncovered by the granule).
  • the width of the peak is defined as the dimension at half height and is orthogonal to the height of the peak.
  • a dimension of the valley can be characterized by breadth ("B”), which is the shortest distance at the floor of the valley between any two peaks that define the valley.
  • an implantable device comprising: a device body; and a textured surface layer overlying the device body, wherein the textured surface layer comprises one or more granules of a microporous biomaterial, the granules forming a surface macrotopography that includes a plurality of peaks and valleys, each peak having a height of between about 100 micrometers and about 2000 micrometers, and wherein each granule comprises a plurality of interconnecting pores having a mean pore diameter of between about 5 and 100 micrometers, and any two adjacent pores are connected by a throat, a mean throat diameter of the throats being between 5 and 50 micrometers.
  • the phrase “about” refers to a range of values ⁇ 20% of a specified value.
  • the phrase “about 100 micrometers” includes a range of ⁇ 20% of 100 micrometers, namely, 80 to 120 micrometers.
  • the peaks have heights between about 200 micrometers and about 1000 micrometers, between about 500 micrometers and about 2000 micrometers, or between about 500 micrometers and about 1000 micrometers.
  • the interconnecting pores have a mean pore diameter of at least about 10 ⁇ and not more than about 90 ⁇ .
  • the range of diameters of porogens is less, e.g., from about 20 ⁇ to about 75 ⁇ , from about 20 ⁇ to about 30 ⁇ , from about 30 ⁇ to about 60 ⁇ , or from about 30 ⁇ to about 40 ⁇ .
  • the granules are distributed in a single layer (i.e., a monolayer).
  • Figure 5 is an SEM of an implantable device 80 comprising a solid silicone layer 84 and a monolayer surface of granules of 300-500 micrometers formed of sphere - templated microporous silicone. The macrotopography of the monolayer surface is defined by peaks 90 and valleys 94.
  • the entire internal surface area of the interconnecting pores of the microporous surface layer may over time become covered by host macrophages.
  • these microporous tissue scaffolds encourage ingrowth of host macrophages, and release by these cells of clinically desirable factors such as anti-fibrotic and pro-angiogenic factors.
  • the bioavailable surface area may be maximized, which in turn results in a maximum local concentration of macrophages on the internal surface of the scaffold. If the microporous biomaterial is at least several pore layers thick, then the local
  • concentration of these beneficial factors may vary as a function of the concentration of the surface pores that are in direct contact with the surrounding tissue.
  • concentration of “surface pores” can be more than doubled and the availability of such factors amplified, relative to non-textured microporous surfaces.
  • surface pores refers to the outermost layer of pores within a microporous surface layer of an implantable device. When the implantable device is implanted, the surface pores are directly exposed to the surrounding tissue.
  • the term “surrounding tissue” also includes tissue that grows into the spaces between the macrotopographic features of the microporous biomaterial.
  • tissue interface layer refers to the tissue layer that includes both the tissue that grows into the pores within the peaks as well as the tissue that grows into the spaces between the peaks.
  • the tissue interface layer does not include the portion of the surrounding tissue that is beyond the height of the peaks.
  • concentration of surface pores per unit volume within the tissue interface layer is higher for smaller peaks than for larger ones.
  • individual granules 100a, 100b and 100c are in an ascending order of sizes, which correlate to a descending order of the surface
  • concentrations of surface pores 110a, 110b and 110c concentrations of surface pores 110a, 110b and 110c.
  • Such correlation between the granule size and surface concentration of surface pores may favor the use of smaller granules according to certain embodiments described herein.
  • the peaks are too small (e.g., smaller than 100 micrometers), there may not be enough total pores to accommodate a large enough reservoir of macrophages, such that from the present disclosure the skilled person will appreciate that selection of an appropriate dimension may vary depending on the particular microporous scaffold.
  • Surface pore concentration per unit projected area is influenced by the height-to-width ratio of the granule or the peak.
  • the height-to-width ratio of the peaks that comprise the macrotopographic features should be greater than 1 :2, more preferably greater than 1 : 1, and most preferably greater than 2: 1.
  • the shape and/or size of the valley in the surface macrotopography potentially play a role in amplifying the effects of pro-angiogenic and anti-fibrotic factors.
  • these factors are released into the valleys between peaks, their diffusion into the tissue can be slowed down by the confining geometry.
  • the breadths of the valleys are narrow enough to create "coves," which are valleys that have breadths equal to or less than the width of the peaks surrounding the valleys, the favorable factors released from the surface pores of the neighboring peaks can accumulate and remain in the vicinity of the interface longer, compounding the amplification of their effects.
  • the microporous surface layer can be further characterized by packing density or surface coverage (in percentage) of granules on a native surface of the device body.
  • an intermediate layer e.g., a conformal adhesive layer or a sheath
  • the intermediate layer is treated as if it is a native surface of the device body.
  • each granule may or may not be in contact with several other granules.
  • the packing density of a layer of granules on the surface can be increased by applying successively smaller size fractions of granules in separate steps.
  • Size fraction refers to a population of granules of substantially the same size obtained, for example, by size sorting such as sieving. When the granules are applied in this way, smaller granules are available to fill the spaces between the larger granules as shown in Figure 7.
  • the granules may be substantially uniform sized or a mixture of different sizes. When granules are of uniform size, approximately 65% of the surface is covered ( Figure 7, panel A). By using a mixture of sizes, slightly more coverage is achieved ( Figure 7, panel B). Even more coverage is obtained by using two different sizes of granules (about 80% coverage, Figure 7, panel C). The most coverage - about 90% - is achieved by successive application of granules starting with the largest size and then applying the next smaller size and so on (Figure 7, panel D).
  • various embodiments describe implantable devices in which the granules cover more than 80%, or more than 90% of a total area of the surface of the implantable device.
  • implantable devices with textured, granular surface layers can be fabricated by applying (e.g., sprinkling) granules to the surface of device bodies, especially those of large and/or irregular shapes.
  • devices such as breast implants and percutaneous devices, where minimizing of the foreign body capsule is needed but mass transfer through the pores of the scaffold is not required, are well-suited for the direct application the granules.
  • the surfaces that define the tops and sides of the peaks are microporous
  • the surfaces of the bottoms of the valleys i.e., valley floors
  • the microporous biomaterial is connected to a nonporous intermediate layer impermeable to cells.
  • FIG. 8 A further example of this mode of application is shown in Figure 8, in which a polypropylene mesh for surgical hernia repair coated or dusted with porous granules that adhere to the surface of the mesh.
  • the coated mesh may have varying degrees of coverage.
  • the porous granules coat only the mesh filaments such that the original openings between the mesh filaments are substantially exposed.
  • porogens A variety of materials and methodologies are known for the production of a porous biocompatible material and may be adapted to produce the microporous biomaterial with pores of specific geometries and sizes. Templates for the pore formation are referred to as "porogens.” For certain microporous biomaterial, the porogens are also referred to as “micro-porogens,” which are sized so that a sphere of the same volume has a diameter ranging from about 5 micrometers to about 100 micrometers.
  • microporous biocompatible materials may be made by (1) sintering or fusing (partially or fully) an array of micro- porogens, (2) casting a biocompatible material into the spaces among fused porogens and then (3) dissolving away, evaporating or otherwise removing the porogens to yield a network of interconnected voids (pores).
  • the partially fused or sintered porogens form what will be the interconnecting throats of the porous material. It is generally most convenient to prepare sintered porogens in a mold.
  • the size of the mold may be any size that is larger than the intended size of granules.
  • a convenient mold size is about 5 cc to 10 cc in volume, e.g., about 3 cm x 2 cm x 1 cm.
  • porogens may be any shape, ⁇ e.g., spherical, cubic, polyhedrons such as dodecahedrons, ellipsoids, cylindrical, irregular), generally porogens are spherical or nearly spherical in shape. Spherical shapes can be efficiently, tightly packed together while still retaining controlled spaces between the porogens, resulting in a highly interconnected network of pores.
  • the porogens may vary in size. However, their sizes are generally controlled and at least a majority, and more typically, substantially all of the porogens have a diameter that is at least about 10 ⁇ and not more than about 90 ⁇ . In some circumstances, the range of diameters of porogens is less, e.g., from about 20 ⁇ to about 75 ⁇ , from about 20 ⁇ to about 30 ⁇ , from about 30 ⁇ to about 60 ⁇ , or from about 30 ⁇ to about 40 ⁇ , e.g., about 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 ⁇ . Size can be controlled by any number of ways.
  • porogens can be sized by sieving or by the manufacturing method used to generate them. In some circumstances, substantially all the porogens have a similar diameter. As used herein, the term “substantially all the porogens” refers to the percentage of porogens within one standard deviation on either side from the mean diameter, within two standard deviations on either side, or within three standard deviations on either side. The term “diameter of a porogen” refers to the longest line segment that can be drawn that connects two points within the pore, regardless of whether the line passes outside the boundary of the pore. In preferred embodiments, the porogens are monodisperse, i.e., the porogens have substantially the same diameters and the difference in the diameters of any two porogens is no more than 20% of the larger diameter.
  • Porogens may be manufactured from a variety of materials. Generally, the material will in certain embodiments be hard and rigid enough to withstand grinding. Many suitable materials are known for such use and may vary depending on the selected biocompatible material in which pore formation is desired, and on the fabrication process that is employed. One such material is polymethylmethacrylate (PMMA). Other examples of suitable hard materials for use as porogens include metals, composites and ceramics. In addition to its hardness, the material needs to be extractable from the biocompatible material forming the scaffold. Chemical extraction using acetone, di- chloromethane or other suitable solvent is typically used, although physical methods that selectively remove porogens ⁇ e.g., by application of heat and/or pressure) may also be used. At times, extraction conditions may involve both chemicals and physical parameters ⁇ e.g. , temperature, elevated pressure, or reduced pressure).
  • the shape and diameter of a pore typically may reflect the shape and diameter of a given porogen.
  • the pores may be slightly smaller or larger ⁇ e.g., ⁇ 1-10% volume) than the loose porogens before they are arrayed and sintered due, in part, to the potential shrinking or swelling of the biomaterial following the removal of the porogens.
  • the diameter and shape of the pores, as well as the connections between them may be assessed using scanning electron microscopy (see, e.g., Figure 1).
  • the diameters of throats (or throat diameter) resulting from packed and fused porogens is between about 15% to about 40% of the mean diameter of the porogens.
  • throat diameter refers to the diameter of the cross-section of the connection between two pores in the plane normal to the line connecting the centroids of the two pores (if pores had uniform mass), where the plane is chosen so that the area of the cross-section of the connection is at its minimum value.
  • packing usually places each porogen in contact with about four to about twelve other porogens.
  • the packed porogen array and the resulting porous biocompatible scaffold which is formed around the porogens can be any thickness and, in certain embodiments described herein, is usually at least 70 ⁇ or most often at least 100 ⁇ .
  • the biocompatible material is typically a polymer or any of a number of other biocompatible materials known to the art that are capable of being formed into granules having volumetric and pore dimensions as described herein, and also being capable of maintaining such dimensions when exposed to biochemical and
  • a typical polymer thus may comprise any biocompatible polymer, such as synthetic polymers, naturally-occurring polymers, or mixtures thereof.
  • exemplary synthetic biocompatible polymers include, but are not limited to, 2-hydroxyethyl methacrylate (HEMA), silicone such as Nusil MED-6215 or other silicone suitable for implantation, poly(epsilon -caprolactone) dimethylacrylate, polysulfone, (poly)methyl methacrylate (PMMA), soluble Teflon- AF, poly ethylene teraphthalate (PET, Dacron), Nylon, polyvinyl alcohol, polyurethane, hydroxyapatite, and mixtures thereof.
  • HEMA 2-hydroxyethyl methacrylate
  • silicone such as Nusil MED-6215 or other silicone suitable for implantation
  • PMMA poly(epsilon -caprolactone) dimethylacrylate
  • PMMA poly(epsilon -caprolactone) dimethylacrylate
  • PMMA poly
  • Exemplary naturally-occurring biocompatible polymers include, but are not limited to, fibrous or globular proteins, complex carbohydrates, glycosaminoglycans, connective tissue extracellular matrix (ECM) components, such as collagen or fibrin, or mixtures thereof.
  • the polymer scaffold may include collagens of all types, elastin, laminin, hyaluronic acid, alginic acid, desmin, versican, matricellular proteins such as SPARC (osteonectin), osteopontin, thrombospondin 1 and 2, fibrin, fibronectin, vitronectin, albumin, etc.
  • Natural polymers may be used as substantial components of the scaffold or as additives to improve the biocompatibility of a scaffold that comprises a synthetic polymer.
  • Other biocompatible materials suitable for forming the porous biomaterial scaffold may include hydroxyapatite and a variety of biocompatible metals including but not restricted to titanium. Further exemplary biocompatible materials can be found in, e.g., U.S.
  • the biocompatible material may in certain embodiments be degradable or bioresorbable. Degradation may occur via natural processes such as in vivo metabolic pathways, or by hydrolysis or following treatment with, e.g. , an enzyme or chemical that acts upon the biocompatible material.
  • the biocompatible material may comprise crosslinked hyaluronic acid and may be degraded by
  • biodegradable materials include fibrin and collagen.
  • fibrin and collagen For some applications, it may be desirable to use granules comprising combinations of biodegradable materials that degrade at different rates.
  • the biocompatible material may in certain embodiments possess bioactivity due to incorporation into the material of a biologically active ingredient, or may be made partially or solely of a bioactive substance, such as salicylic acid, or of a substance that responds to electrical stimulation, such as polyaminoarenes.
  • the biocompatible material may also be composed partially or solely of an electrically conducting polymer, or the surface of the biomaterial may be metalized.
  • granules may be applied to a surface of the device body to provide surface topographic features, including peaks and valleys.
  • granules of porous biocompatible material may comprise pieces of a larger material.
  • a biocompatible material - before porogens are extracted - may be mechanically broken into smaller pieces by grinding, shattering, shearing, sonicating, or the like, to obtain granules.
  • Granules of a desired size can be selected from the resultant population of granules.
  • a coffee grinder is a suitable machine.
  • Other suitable devices include blenders, crushers, sonicators, hammers, mills, and pulverizers, and the like.
  • a porous biocompatible material is manufactured and granules are obtained before the porogens are extracted. With porogens present, the material has increased physical integrity, allowing it to better withstand granulization.
  • the porous biocompatible biomaterial can also be formed into granules after extraction of the porogens.
  • An exemplary suitable method for polymers comprises freezing the material into rigid form before grinding. Detailed descriptions of preparing granules can also be found in co-pending International Patent Application No. PCT/US2010/26107 (in the name of Healionics Corporation, the assignee of the present disclosure), which is incorporated herein by reference in its entirety.
  • Granules obtained by any of the described methods may be subsequently sieved to obtain a preparation of granules that are substantially within a specific size range.
  • size ranges of granules There are both practical and biological considerations regarding size ranges of granules. Practically, manufacturing a porous granule of a size having a diameter that is only a few times the average diameter of the pores can be difficult. Further and in a biological context, following emplacement in vivo such granules may not present sufficient interstitial spaces to enable angiogenesis of larger blood vessels, and/or they may block continuity of a blood vessel channel between the granules.
  • granules that are too small should be discarded. Conversely, when granules are too large ⁇ e.g., more than 2 mm diameter), there may be insufficient tissue ingrowth through the porous biocompatible material and the granules may be difficult to apply or position.
  • the sizes of the granules are expressed in terms of dimensions ⁇ e.g., diameters) as determined by passing through a mesh or sieve having specifically sized mesh openings.
  • granules may be sieved or otherwise sized to yield a size range from about 0.1 mm to about 2 mm, from about 0.1 mm to about 1 mm, from about 0.1 mm to about 0.8 mm, from about 0.1 mm to about 0.6 mm, from about 0.1 mm to about 0.4 mm, from about 0.1 mm to about 0.2 mm, from about 0.2 mm to about 2 mm, from about 0.2 mm to about 1 mm, from about 0.2 mm to about 0.8 mm, from about 0.2 mm to about 0.6 mm, from about 0.2 mm to about 0.4 mm, from about 0.2 mm to about 0.3 mm, from about 0.3 mm to about 2 mm, from about 0.3 mm to about 1 mm, from about 0.3 mm to
  • the size of a granule can be expressed as the diameter of a sphere that has substantially the same volume.
  • a granule is characterized by its "diameter equivalent” it should be understood that the term refers to the diameter of a sphere with substantially the same volume as a granule. "Substantially the same” refers to at least 70, 75, 80, 85, 90, 95, 96, 97, 98 or 99% and not more than 130, 125, 120, 110, 105, 104, 103, 102, 101 or 100% of the volume of the granule.
  • the granules prepared as described herein are, although generally irregularly-shaped, approximately spherical in shape or have an aspect ratio of no more than 5, or more preferably, no more than 4, or more preferably no more than 3 (see, e.g., Figure 1).
  • the term "aspect ratio" refers to the ratio of the largest dimension divided by the smallest dimension of a granule.
  • the aspect ratio may or may not be the same as the height to width ratio of a granule that forms a peak.
  • the heights of granules in a monolayer of the same correlate to the height of the peaks of the surface macrotopography, as defined herein.
  • the porogens may be extracted by chemical or physical method appropriate to the composition of the porogen and of the granules (i.e., the biocompatible material).
  • granules may then be coated or impregnated with a chemical or biological substance, such as a drug, growth factor, or sensor of body condition. Coating may be accomplished by dipping (or by suspending, bathing, rinsing, spraying, etc., or other method of contacting) granules in the chemical or biological substance, presented either in liquid or dry form. More uniform and quantitative coating can be obtained with the chemical or biological substance in liquid form. Higher amounts of loading can be obtained by first swelling the granules in a solvent.
  • soaking silicone granules in a protein-loaded suspension or solution comprising a solvent such as isopropanol causes the silicone to swell and take up the protein-loaded liquid.
  • the solvent is then evaporated, resulting in granules that have incorporated the protein (or other chemical or biological substance) into the bulk.
  • a solvent will depend in part on the composition of the biocompatible material and of the substance to be loaded.
  • a solvent that swells the biomaterial substrate and dissolves the substance without deactivating the substance may be desirable in these and related embodiments. Any substance that dissolves in a solvent without deactivating the substance can be incorporated this way.
  • Solvents for the substance that do not swell the biomaterial substrate may also be used to load the substance into the pore surfaces or open volumes without incorporating the substance into the bulk of the substrate.
  • suitable solvents include xylene and other benzene derivatives, isopropanol, acetone and other ketones, and chlorohydrocarbons such as dichloromethane.
  • Chemical substances may, in certain contemplated embodiments, include chemicals that are sensitive to a stimulus, such as ultrasound, electrical impulse, electromagnetic radiation, light, or temperature. These may include chemicals that are sensitive to levels of oxygen or glucose in the body and that are capable, for instance, of displaying glucose-proportional fluorescence when activated by light.
  • Molecules capable of exhibiting glucose-sensitive fluorescence include fluorescein isothiocyanate-labeled dextran, concanavalin A, rhodamine-concanavalin A, glucose oxidase, glucose
  • Biological substances may, in certain contemplated embodiments, include growth factors (e.g., fibroblast growth factors, stem cell growth factors, platelet- derived growth factor, transforming growth factor beta, insulin-like growth factors, epidermal growth factor, vascular endothelial growth factor, angiopoietins, interleukins, granulocyte-colony stimulating factor, granulocyte macrophage colony stimulating factor, nerve growth factor, and keratinocyte growth factor), vitamins (e.g., vitamin A, vitamin C, vitamin E), fibrinogen, fibronectin, bone morphogenetic proteins, cytokines such as interleukins, lymphokines, chemokines, tumor necrosis factor-a, and interferons, leptins, cell adhesion molecules or portions thereof (e.g., RGD peptides, ICAM,
  • Granules may also be surface-modified with substances that are hydrophilic, such as polyethylene glycol or tetraglyme or alumina; and/or that are hydrophobic, such as polytetrafluoroethylene or silicone; and/or that increase lubricity, such as hyaluronic acid; and/or that improve cell adhesion, such as carbonyldiimidazole (with or without coupled proteins such as collagen); and/or that are radiopaque, such as noble metals; and/or or that are antimicrobial, such as silver ions or antimicrobial peptides, among others.
  • modifying the surfaces of granules with RGD (arginine- glycine-aspartic acid) peptides may increase cell adhesion to granules.
  • Granules may also be sterilized in a variety of ways.
  • the granules may be sterilized with ethylene oxide gas, irradiated, autoclaved, or soaked in organic solvents, or sterilized by other ways known to those skilled in the art.
  • granules are attached to a device body by any known methods of effecting adherence.
  • the granules are attached directly to a device body.
  • an intermediate layer e.g. , an adhesive or a conformal sheath
  • the intermediate layer covers a part of or an entire native surface of the device body.
  • a related embodiment provides a method for forming an implantable device having a device body and a microporous surface layer, comprising:
  • An exemplary method for attaching granules is to apply an adhesive material to one or more surfaces of the device and then contact the granules into the adhesive as diagrammatically shown in Figure 4.
  • Granules may, for example, be sprinkled on, or the device may be rolled in granules, or granules may be sprayed on the device, or applied with a tool or machine.
  • the granules are contacted with the device, or with an adhesive, at least to the extent that surface portions of the granules are in contact with the adhesive. This will leave the interior of the granules and some surfaces of the granules substantially free of adhesive, to allow for tissue in-growth.
  • granules may comprise or contain a substance that can act as a glue (as used herein, the terms “adhesive” and a “glue” are used interchangeably) under appropriate conditions.
  • the glue in the granules may be appropriately activated (e.g. , by heat, chemical, or light) and the granules may be contacted with the device.
  • the adhesive is biocompatible.
  • Some biocompatible adhesives are silicone, fibrin, fibrinogen, chitosan, calcium phosphate cement,
  • Example materials appropriate for adhesion of the granules to a device surface include silicones such as Nusil MED 6400, or Nusil MED2 4213,
  • natural glues may include those produced by a variety of marine animals (e.g. , molluscs, sea stars), worms, bacteria, fungi, amphibians, spiders, insects, and algae (Graham,
  • Biocompatible adhesives are well known in fields of wound dressings, dentistry, surgery, especially bone surgery and tissue repair and drug delivery via patches.
  • an elastic conformal sheath or overcoat for the device body it may be advantageous to prepare an elastic conformal sheath or overcoat for the device body, and to first attach the granules to this sheath.
  • the sheath will be made from an elastic polymer and constructed over a mandrel reproducing the dimensions of the target device. Frequently the mandrel will be made in the same proportions as the target but undersized by about 5% to about 25% in dimensions, most often by about 10% to 20%. This allows the sheath to be elastically form fitted to the target device. It may be adhered to the device to retain location or prevent fluid ingress.
  • the sheath will have at least one opening to allow removal from the mandrel and placement on the target device.
  • Such a sheath covered with granules is of particular utility when the processes required to adhere granules directly to a device surface are incompatible with the device materials. For example the temperature required to cure granule attachment adhesive may be in excess of that tolerated by the target device. Other situations may include mechanical forces or chemical interactions.
  • Such a sheath may have substantially continuous walls other than at the opening or on other useful occasions be made of a mesh or other structure providing fluid communication through the thickness of the sheath after the granules are applied.
  • the necessary opening in the sheath may be filled by a variety of means after the granule coated sheath is applied to the device.
  • Such means may include but are not limited to; solid elastomeric sheets, sheets of porous material, further sheets of granule covered material, active sensor or activator ports, electrical, pneumatic fluid or other connections.
  • granules will be applied to the surface of the device body (with or with the intermediate layer) in such a way that the granules form a monolayer with a desired surface coverage.
  • all native surfaces of the device are covered in granules (i.e., surface coverage is or close to 100%).
  • Other devices may, for instance, be attached directly to the device, or a sensor or biostimulating portion of the device may operate by direct tissue contact, or some other device portion may desirably remain uncovered. In such cases, granules may be attached to only a portion of the device.
  • Masking means as commonly employed to control the deposition of materials on a surface may be used to create the desired pattern.
  • the microporous surface layer has a continuous contour with surface
  • the microporous surface layer may include interconnecting micropores throughout the entire layer in a continuous open-cell construction.
  • Figure 9 is an SEM of a continuous open-cell scaffold 130. As shown, substantially all of the tops and sides of the peaks 134, and bottoms of the depressions or valleys 140 between the peaks, contain continuously interconnecting pores, which enable cellular ingrowth into the open-cell structure.
  • Figure 10 shows the microporous structure of a single peak of a continuous open-cell scaffold.
  • one embodiment provides a microporous biomaterial with
  • the microporous biomaterial has a continuous contour and continuously interconnecting pores, wherein substantially all the pores are each interconnected to at least 2 other pores, a mean diameter of the pores is between about 5 and about 100 micrometers, and any two adjacent pores are connected by a throat, a mean throat diameter of the throats being between about 5 micrometers and about 50 micrometers, and wherein the macrotopography is defined by a plurality of peaks and valleys, wherein each peak comprises a plurality of pores and has a height of between about 100 micrometers and about 2000 micrometers.
  • a further embodiment provides an implantable device having a device body and A microporous biomaterial with macrotopographic surface features, wherein the microporous biomaterial has a continuous contour and continuously interconnecting pores, wherein substantially all the pores are each interconnected to at least 2 other pores, a mean diameter of the pores is between about 5 and about 100 micrometers, and any two adjacent pores are connected by a throat, a mean throat diameter of the throats being between about 5 micrometers and about 50 micrometers, and wherein the macrotopography is defined by a plurality of peaks and valleys, wherein each peak comprises a plurality of pores and has a height of between about 100 micrometers and about 2000 micrometers.
  • the height of the peaks that define the macrotopographic features can be between 100 and 2000 micrometers in heights, between about 200 micrometers and about 1000 micrometers, between about 500 micrometers and about 2000 micrometers, or between about 500 micrometers and about 1000 micrometers. More preferably, the height of the peaks will be between 300 and 500 micrometers.
  • the microporous surface layer has a thickness of at least 40 micrometers while excluding the height of the peaks.
  • the open-cell construction is suitable as a surface layer for implantable devices that measure or monitor certain analytes in the tissue.
  • the open-cell structure allows analytes to pass through the pores of the microporous surface layer from the surrounding tissue to the device body, as in the case of a glucose monitor.
  • the implantable device delivers drugs, proteins, or biologic agents, which pass through the pores of the microporous surface layer to reach the surrounding tissue, as in the case of a pancreatic islet isolation capsule.
  • the microporous scaffold in an open-cell structure can be prepared by employing (1) micro-porogens as templates for forming the micropores throughout the scaffold (as discussed above) and (2) macro-porogens as templates for forming the surface macrotopographic features.
  • micro-porogens refers to a porogen sized so that a sphere of the same volume has a diameter ranging from about 100 micrometers to about 2000 micrometers.
  • Suitable material for macro-porogens includes salt crystals and the like.
  • the macrotopography can also be defined by known methods including rapid prototyping.
  • a further embodiment provides a method for forming a microporous biomaterial with macrotopographic features, the method comprising:
  • micro-porogens such that points of contact and interstitial spaces between adjacent micro-porogens are formed, wherein the micro-porogens have a mean micro-porogen diameter that is between about 5 micrometers and about 100 micrometers;
  • the macro-porogens can be removed by, for example, solvent dissolution or chemical dissolution.
  • macro-porogens formed of salt crystals can be dissolved by water.
  • Macro-porogens formed of polymer beads can be dissolved by an organic solvent.
  • solidifying the biocompatible polymer precursor can be accomplished thermally (e.g., curing) or chemically (e.g., polymerization).
  • the dissolvable mold surface is poly(methyl methacrylate) or polystyrene.
  • micropores can also be formed by a number of known methods for forming open-cell porous materials, including, but not limited to, gas foaming, particle sintering, salt-leaching, polymer bead leaching, phase separation, and rapid prototyping.
  • the macrotopography as hills and valleys on one side of the substantially flat porous base portion, that the macrotopography may be formed from both surfaces of such a base, or in general to any shape of a substantially continuous base.
  • Implanted devices that have a textured, microporous surface layer may better integrate with the surrounding tissue, thus avoiding undesirable effects caused by foreign body responses.
  • the surface texture or macrotopographic features such as those formed by porous granules attached to the device as described herein, allow tissue penetration into the micropores and between the peaks of the surface
  • one embodiment provides a method of implanting a microporous biomaterial with macrotopographic surface features, wherein the microporous biomaterial has a continuous contour and continuously interconnecting pores, wherein substantially all the pores are each interconnected to at least 2 other pores, a mean diameter of the pores is between about 5 and about 100 micrometers, and any two adjacent pores are connected by a throat, a mean throat diameter of the throats being between about 5 micrometers and about 50 micrometers, and wherein the macrotopography is defined by a plurality of peaks and valleys, wherein each peak comprises a plurality of pores and has a height of between about 100 micrometers and about 2000 micrometers.
  • a further embodiment contemplated herein provides a method comprising implanting an implantable device having a device body; and a microporous surface layer with macrotopographic features, wherein the microporous surface layer has a continuous contour and continuously interconnecting pores, wherein substantially all the pores are each interconnected to at least 2 other pores, a mean diameter of the pores is between about 5 and about 100 micrometers, and any two adjacent pores are connected by a throat, a mean throat diameter of the throats being between about 5 micrometers and about 50 micrometers, and wherein the macrotopography is defined by a plurality of peaks and valleys, wherein each peak comprises a plurality of pores and has a height of between about 100 micrometers and about 2000 micrometers.
  • Another embodiment provides a method comprising implanting an implantable device comprising a device body; and a textured surface layer overlying the device body, wherein the textured surface layer comprises one or more granules of a microporous biomaterial, the granules forming a surface macrotopography that includes a plurality of peaks and valleys, each peak having a height of between about 100
  • each granule comprises a plurality of interconnecting pores having a mean pore diameter of between about 5 and 100 micrometers, and any two adjacent pores are connected by a throat, a mean throat diameter of the throats being between 5 and 50 micrometers.
  • a further embodiment provides a method for avoiding thickening a foreign body capsule that forms in a tissue around an implanted device as a result of foreign body response by implanting the implantable device with the surface features as described herein.
  • a further embodiment provides a method for promoting angiogenesis in and around an implanted device by implanting the implantable device with the surface features as described herein.
  • This example describes production of granules made of a porous biocompatible material.
  • PMMA Poly(methyl methacrylate) (PMMA) beads with diameter 36 micrometers +1- 2 micrometers were added to poly ether ether ketone (PEEK) molds consisting of a cavity about 3 cm long x2 cm wide x 0.5 cm deep, and sintered for 19 hours at 190 degrees C. to give neck sizes of about 40% of the bead diameter.
  • PEEK poly ether ether ketone
  • the mixture was allowed to polymerize for 24 hours to provide polyHEMA impregnated with PMMA beads.
  • the polymer was ground with a rotary blade coffee grinder. Granules were sieved, and the size fraction passing through 0.7 mm openings, but retained by 0.3 mm openings, was collected for use.
  • the PMMA pore templates were removed from the granules by Soxhlet extraction in dichloromethane.
  • the granules were transferred to acetone to swell the polyHEMA, then rinsed by Soxhlet extraction in endotoxin-free water for 2 hours with the condenser turned off (to boil off the acetone and dichloromethane) followed by 4 hours of Soxhlet rinsing with the condenser running.
  • thermoplastic acrylic beads were thoroughly sieved between meshes of 25 ⁇ and 35 ⁇ opening sizes using a RX-29 RoTap automatic sieve shaker (WS Tyler, Mento, OH) to remove undersized beads as well as any macro size particulate contaminants larger than the beads.
  • the beads were transferred to a rectangular mold (3 cm x 2 cm x 1 cm) and placed in a convection oven for 20h at 180°C to sinter the beads to approximately 11 ⁇ interbead neck diameter.
  • the sintered bead "brick” was removed from the mold and impregnated with catalyzed NuSil MED-4211 silicone by centrifugation for lh at 30,000 - g. After impregnation with silicone, the brick was placed in an oven at 80°C for 16h to cure the silicone.
  • a rotary blade coffee grinder was used to grind the brick into granules approximately 400 ⁇ in diameter. The granules were then thoroughly sieved with a RoTap automatic sieve shaker to remove particles smaller than 300 ⁇ or larger than 500 ⁇ . Light microscopy was used to verify that >90% of granules of were within the target range.
  • a 0.6 mm layer of Dow Corning MDX4-4210 silicone was cast in a mold and cured per manufacturer's guidelines.
  • NuSil MED-6400 silicone was mixed and degassed by centrifugation, then poured over the MDX4-4210 sheet.
  • the substrate was oriented vertically to allow the excess MED-6400 allowed to flow off.
  • the xylene solvent (a component of the MED- 6400) was allowed to evaporate to leave a high-viscosity adhesive surface.

Abstract

La présente invention divulgue des dispositifs implantables revêtus de couches de surface microporeuses présentant des caractéristiques macro-topographiques qui améliorent la bio-intégration à l'interface des dispositifs implantables et des tissus environnants.
PCT/US2010/058078 2009-11-25 2010-11-24 Dispositifs médicaux implantables comportant des couches de surface microporeuses et procédé pour réduire la réponse des corps étrangers à ceux-ci WO2011066441A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US13/082,760 US8372423B2 (en) 2009-11-25 2011-04-08 Implantable medical devices having microporous surface layers and method for reducing foreign body response to the same
EP11724832.8A EP2555810B1 (fr) 2010-04-08 2011-04-08 Dispositifs médicaux implantables ayant couches de surface microporeuses et procédé de réduction de réponse à un corps étranger pour ceux-ci
CN201180027977.7A CN103037911B (zh) 2010-04-08 2011-04-08 具有微孔表面层的植入式医学装置及降低针对所述装置的异物反应的方法
PCT/US2011/031764 WO2011127395A1 (fr) 2010-04-08 2011-04-08 Dispositifs médicaux implantables ayant couches de surface microporeuses et procédé de réduction de réponse à un corps étranger pour ceux-ci
KR1020127029276A KR101813300B1 (ko) 2010-04-08 2011-04-08 미세다공성 표면 층을 가지는 이식형 의료 장치 및 이에 대한 이물 반응을 감소시키는 방법
US13/718,847 US8647393B2 (en) 2009-11-25 2012-12-18 Implantable medical devices having microporous surface layers and method for reducing foreign body response to the same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US26458509P 2009-11-25 2009-11-25
US61/264,585 2009-11-25
PCT/US2010/026107 WO2011065987A1 (fr) 2009-11-25 2010-03-03 Granules de matériaux poreux biocompatibles
USPCT/US2010/026107 2010-03-03
US32228210P 2010-04-08 2010-04-08
US61/322,282 2010-04-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/082,760 Continuation-In-Part US8372423B2 (en) 2009-11-25 2011-04-08 Implantable medical devices having microporous surface layers and method for reducing foreign body response to the same

Publications (1)

Publication Number Publication Date
WO2011066441A1 true WO2011066441A1 (fr) 2011-06-03

Family

ID=43479348

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/058078 WO2011066441A1 (fr) 2009-11-25 2010-11-24 Dispositifs médicaux implantables comportant des couches de surface microporeuses et procédé pour réduire la réponse des corps étrangers à ceux-ci

Country Status (1)

Country Link
WO (1) WO2011066441A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014052724A1 (fr) * 2012-09-28 2014-04-03 Allergan, Inc. Compositions porogènes, procédés de fabrication et utilisations
US9138310B2 (en) 2007-11-05 2015-09-22 Allergan, Inc. Soft prosthesis shell texturing method
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9155613B2 (en) 2010-11-16 2015-10-13 Allergan, Inc. Methods for creating foam-like texture
US9205577B2 (en) 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
WO2016210346A1 (fr) * 2015-06-24 2016-12-29 Healionics Corporation Dispositif poreux injectable pour le traitement de rétinopathie diabétique et de dégénérescence maculaire liée à l'âge par voie humide ou sèche
US9593224B2 (en) 2010-09-28 2017-03-14 Allergan, Inc. Porogen compositions, methods of making and uses
US10092392B2 (en) 2014-05-16 2018-10-09 Allergan, Inc. Textured breast implant and methods of making same
US10765501B2 (en) 2008-08-13 2020-09-08 Allergan, Inc. Dual plane breast implant
US10864661B2 (en) 2012-12-13 2020-12-15 Allergan, Inc. Device and method for making a variable surface breast implant
US11202853B2 (en) 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
WO2022061007A1 (fr) * 2020-09-16 2022-03-24 Encellin, Inc. Dispositifs d'encapsulation de cellules et leurs procédés d'utilisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040086548A1 (en) * 2002-11-06 2004-05-06 St. John John V. Shape-retentive hydrogel particle aggregates and their uses
WO2005032418A2 (fr) * 2003-10-01 2005-04-14 University Of Washington Nouveaux biomateriaux poreux
US20080200430A1 (en) 2007-02-21 2008-08-21 Bitterman Robert J Methods of Use of Biomaterial and Injectable Implant Containing Biomaterial
US20090012625A1 (en) 2004-09-14 2009-01-08 Ying Jackie Y Porous biomaterial-filler composite and method for making the same
US20100026107A1 (en) 2008-07-30 2010-02-04 Hitachi Kodki Co., Ltd. Power tool

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040086548A1 (en) * 2002-11-06 2004-05-06 St. John John V. Shape-retentive hydrogel particle aggregates and their uses
WO2005032418A2 (fr) * 2003-10-01 2005-04-14 University Of Washington Nouveaux biomateriaux poreux
US20080075752A1 (en) 2003-10-01 2008-03-27 University Of Washington Novel Porous Biomaterials
US20090012625A1 (en) 2004-09-14 2009-01-08 Ying Jackie Y Porous biomaterial-filler composite and method for making the same
US20080200430A1 (en) 2007-02-21 2008-08-21 Bitterman Robert J Methods of Use of Biomaterial and Injectable Implant Containing Biomaterial
US20100026107A1 (en) 2008-07-30 2010-02-04 Hitachi Kodki Co., Ltd. Power tool

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BAMSLEY GP ET AL., PLAST RECONSTR SURG, vol. 117, 2006, pages 2182
BARONE F.E. ET AL., PLAST RECONSTR SURG, vol. 90, 1992, pages 77
BRAUKER J.H. ET AL., J BIOMED MATER RES, vol. 29, 1995, pages 1517
E.G., OATES ET AL., BIOMATERIALS, vol. 28, 2007, pages 3679
GRAHAM: "Encyclopedia of Biomaterials and Biomedical Engineering", 2005, INFORMA HEALTHCARE, article "Biological Adhesives from Nature"
HENRIKSEN T.F. ET AL., ANN PLAST SURG, vol. 54, 2005, pages 343
MARSHALL A.J. ET AL., POLYMER PREPRINTS, vol. 45, 2004, pages 100
PAUL N.E. ET AL., BIOMATERIALS, vol. 29, 2008, pages 4056 - 64
ROSENGREN ET AL., JBIOMED MATER RES, vol. 67A, 2003, pages 918
SHARKAWY A.A. ET AL., J BIOMED MATER RES, vol. 40, 1998, pages 586

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138310B2 (en) 2007-11-05 2015-09-22 Allergan, Inc. Soft prosthesis shell texturing method
US10765501B2 (en) 2008-08-13 2020-09-08 Allergan, Inc. Dual plane breast implant
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US10391199B2 (en) 2010-02-05 2019-08-27 Allergan, Inc. Porous materials, methods of making and uses
US10624997B2 (en) 2010-02-05 2020-04-21 Allergan, Inc. Porogen compositions, methods of making and uses
US11202853B2 (en) 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
US9593224B2 (en) 2010-09-28 2017-03-14 Allergan, Inc. Porogen compositions, methods of making and uses
US9155613B2 (en) 2010-11-16 2015-10-13 Allergan, Inc. Methods for creating foam-like texture
WO2014052724A1 (fr) * 2012-09-28 2014-04-03 Allergan, Inc. Compositions porogènes, procédés de fabrication et utilisations
US10864661B2 (en) 2012-12-13 2020-12-15 Allergan, Inc. Device and method for making a variable surface breast implant
US10350055B2 (en) 2014-05-16 2019-07-16 Allergan, Inc. Textured breast implant and methods of making same
US10092392B2 (en) 2014-05-16 2018-10-09 Allergan, Inc. Textured breast implant and methods of making same
US10842916B2 (en) 2015-06-24 2020-11-24 Healionics Corporation Injectable porous device for treatment of dry and wet age-related macular degeneration or diabetic retinopathy
WO2016210346A1 (fr) * 2015-06-24 2016-12-29 Healionics Corporation Dispositif poreux injectable pour le traitement de rétinopathie diabétique et de dégénérescence maculaire liée à l'âge par voie humide ou sèche
WO2022061007A1 (fr) * 2020-09-16 2022-03-24 Encellin, Inc. Dispositifs d'encapsulation de cellules et leurs procédés d'utilisation

Similar Documents

Publication Publication Date Title
EP2555810B1 (fr) Dispositifs médicaux implantables ayant couches de surface microporeuses et procédé de réduction de réponse à un corps étranger pour ceux-ci
WO2011066441A1 (fr) Dispositifs médicaux implantables comportant des couches de surface microporeuses et procédé pour réduire la réponse des corps étrangers à ceux-ci
AU2010325158B2 (en) Granules of porous biocompatible materials
CN107847633B (zh) 用于增强愈合的双层设备
Buyuksungur et al. 3D printed poly (ε-caprolactone) scaffolds modified with hydroxyapatite and poly (propylene fumarate) and their effects on the healing of rabbit femur defects
Antmen et al. The role of biomaterials and scaffolds in immune responses in regenerative medicine: macrophage phenotype modulation by biomaterial properties and scaffold architectures
JP5111731B2 (ja) 網状エラストマーマトリックス、その製造および埋込み可能な装置での使用
KR101499084B1 (ko) 금속 산화물 스캐폴드
Capuani et al. Advanced strategies to thwart foreign body response to implantable devices
US10092507B2 (en) Implantable cellular and biotherapeutic agent delivery canister
CN113527749B (zh) 一种在聚醚醚酮表面制备多尺度多孔结构的方法
KR101617434B1 (ko) 생분해성 생체고분자를 이용한 다층구조의 연골지지체 제조방법
US20200179121A1 (en) An implantable medical device
EP2286822A1 (fr) Traitement du diabète
CN108578780B (zh) 一种载银离子具有力学梯度的人工骨支架的制备方法
EP2450066A1 (fr) Nouvel implant hybride
Suhail et al. Fabrication of bioactive nano assimilated polymeric scaffold for the metamorphosis of organs or tissues: triumph, confrontation and prospective
KR20120124796A (ko) 생체분해성 고분자가 코팅된 실리콘 임플란트 재료 및 그 제조방법
JP7433692B2 (ja) 異物反応が低減された三次元埋入型マトリックス
TWI615136B (zh) 椎間植入物及其製備方法
CN219089780U (zh) 一种节段骨复合多孔支架
CN116158891A (zh) 一种节段骨复合多孔支架及其制备方法
Fisher et al. Immune-instructive materials and surfaces for medical applications
CN116637233A (zh) 一种合成骨修复材料及其制备方法和使用方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10790806

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10790806

Country of ref document: EP

Kind code of ref document: A1